The estimated Net Worth of Ventures Iii Lp Cw is at least $455 Milhão dollars as of 6 November 2003. Ventures Cw owns over 395,000 units of Illumina Inc stock worth over $452,558,807 and over the last 21 years Ventures sold ILMN stock worth over $2,389,750.
Ventures has made over 1 trades of the Illumina Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently Ventures sold 395,000 units of ILMN stock worth $2,389,750 on 6 November 2003.
The largest trade Ventures's ever made was selling 395,000 units of Illumina Inc stock on 6 November 2003 worth over $2,389,750. On average, Ventures trades about 131,667 units every 0 days since 2003. As of 6 November 2003 Ventures still owns at least 3,625,401 units of Illumina Inc stock.
You can see the complete history of Ventures Cw stock trades at the bottom of the page.
Ventures's mailing address filed with the SEC is C/O CW GROUP, 1041 THIRD AVENUE, NEW YORK, NY, 10021.
Over the last 21 years, insiders at Illumina Inc have traded over $412,190,379 worth of Illumina Inc stock and bought 13,386 units worth $1,243,499 . The most active insiders traders include John Wendell Thompson, Jay T Flatley, eRobert Nelsen. On average, Illumina Inc executives and independent directors trade stock every 5 days with the average trade being worth of $954,700. The most recent stock trade was executed by Jacob Thaysen on 22 February 2024, trading 7,330 units of ILMN stock currently worth $991,676.
at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Illumina Inc executives and other stock owners filed with the SEC include: